JP2014523871A5 - - Google Patents

Info

Publication number

JP2014523871A5

JP2014523871A5 JP2014514917A JP2014514917A JP2014523871A5 JP 2014523871 A5 JP2014523871 A5 JP 2014523871A5 JP 2014514917 A JP2014514917 A JP 2014514917A JP 2014514917 A JP2014514917 A JP 2014514917A JP 2014523871 A5 JP2014523871 A5 JP 2014523871A5

Authority

JP

Japan

Prior art keywords

composition

seq

functional

agent

protein

Prior art date

2012-06-10

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 101000924544 Homo sapiens Angiopoietin-like protein 8 Proteins 0.000 claims description 191
• 102100034604 Angiopoietin-like protein 8 Human genes 0.000 claims description 183
• 239000000203 mixture Substances 0.000 claims description 98
• 239000003795 chemical substances by application Substances 0.000 claims description 94
• 238000000034 method Methods 0.000 claims description 82
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 72
• 150000001413 amino acids Chemical group 0.000 claims description 66
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 60
• 150000007523 nucleic acids Chemical class 0.000 claims description 60
• 108020004707 nucleic acids Proteins 0.000 claims description 52
• 102000039446 nucleic acids Human genes 0.000 claims description 52
• 230000004663 cell proliferation Effects 0.000 claims description 47
• 230000000694 effects Effects 0.000 claims description 43
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 35
• 208000035475 disorder Diseases 0.000 claims description 35
• 210000002237 B-cell of pancreatic islet Anatomy 0.000 claims description 33
• 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 claims description 33
• 102000004877 Insulin Human genes 0.000 claims description 30
• 108090001061 Insulin Proteins 0.000 claims description 30
• 229940125396 insulin Drugs 0.000 claims description 30
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 22
• 108010076504 Protein Sorting Signals Proteins 0.000 claims description 16
• 230000035755 proliferation Effects 0.000 claims description 15
• 101001057154 Homo sapiens Melanoma-associated antigen D2 Proteins 0.000 claims description 14
• 102100027251 Melanoma-associated antigen D2 Human genes 0.000 claims description 14
• 230000003247 decreasing effect Effects 0.000 claims description 14
• 239000003814 drug Substances 0.000 claims description 12
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 10
• 206010012601 diabetes mellitus Diseases 0.000 claims description 10
• 239000002773 nucleotide Substances 0.000 claims description 10
• 125000003729 nucleotide group Chemical group 0.000 claims description 10
• 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 10
• 229940094910 Insulin receptor antagonist Drugs 0.000 claims description 9
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 8
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 8
• 108091028043 Nucleic acid sequence Proteins 0.000 claims description 8
• 239000008280 blood Substances 0.000 claims description 8
• 210000004369 blood Anatomy 0.000 claims description 8
• 239000008103 glucose Substances 0.000 claims description 8
• 238000004519 manufacturing process Methods 0.000 claims description 8
• 230000001225 therapeutic effect Effects 0.000 claims description 8
• 239000013543 active substance Substances 0.000 claims description 6
• 210000004027 cell Anatomy 0.000 claims description 6
• 230000014509 gene expression Effects 0.000 claims description 4
• 230000035772 mutation Effects 0.000 claims description 4
• 102000054765 polymorphisms of proteins Human genes 0.000 claims description 4
• 229940124597 therapeutic agent Drugs 0.000 claims description 3
• 208000002705 Glucose Intolerance Diseases 0.000 claims description 2
• 206010018429 Glucose tolerance impaired Diseases 0.000 claims description 2
• 102000003746 Insulin Receptor Human genes 0.000 claims description 2
• 108010001127 Insulin Receptor Proteins 0.000 claims description 2
• 208000001145 Metabolic Syndrome Diseases 0.000 claims description 2
• 208000008589 Obesity Diseases 0.000 claims description 2
• 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 2
• 235000020824 obesity Nutrition 0.000 claims description 2
• 230000028327 secretion Effects 0.000 claims description 2
• 230000035945 sensitivity Effects 0.000 claims description 2
• 230000001052 transient effect Effects 0.000 claims 2
• 230000002265 prevention Effects 0.000 claims 1
• 239000000463 material Substances 0.000 description 3